Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 927-939

  De Costa, Anna Maria A ^a,b   Schuyler, Corinne A ^a   Walker, David D ^b   Young, M Rita I ^a,b  

^a RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

HNSCC; Immunoediting; Premalignant; Th1 Tc1 cells; Th17 cells

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELLULAR IMMUNITY; CERVICAL LYMPH NODE; CONTROLLED STUDY; EVOLUTION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOPHENOTYPING; LYMPH NODE CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; HEAD AND NECK NEOPLASMS; MICE; MICE, INBRED C57BL; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH17 CELLS;

EID: 84862306564     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1154-8     Document Type: Article

References (37)

1. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345(26):1890-1900. doi:10.1056/NEJMra001375 (Pubitemid 33716564)
2. Hauswald H, Simon C, Hecht S, Debus J, Lindel K (2011) Longterm outcome and patterns of failure in patients with advanced head and neck cancer. Radiat Oncol 6(1):70. doi:10.1186/1748-717X-6-70
3. King GN, Healy CM, Glover MT, Kwan JT, Williams DM, Leigh IM, Worthington HV, Thornhill MH (1995) Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med 332(16):1052-1057. doi:10.1056/NEJM199504203321602
4. Harris JP, Penn I (1981) Immunosuppression and the development of malignancies of the upper airway and related structures. Laryngoscope 91(4):520-528 (Pubitemid 11159702)
5. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R (2008) Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun 8:10
6. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14(12):3706-3715. doi:10.1158/1078-0432.CCR-07-5126
7. + T-cell subpopulations in head and neck cancers. Clin Cancer Res 12(2):465-472. doi:10.1158/1078-0432.CCR- 05-1886
8. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, Collins SL, Petruzzelli GJ (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74(1):69-74 (Pubitemid 27157858)
9. Lathers DM, Achille NJ, Young MR (2003) Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 64(12):1160-1166 (Pubitemid 37475277)
10. Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH (2009) Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 31(7):911-918. doi:10.1002/hed.21040
11. Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA (2007) Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J 86(8):506-511 (Pubitemid 351268069)
12. Zeng X, Chen Q, Nie M (2003) The relationship of Fas and Fas L protein expression in oral carcinogenesis. Hua Xi Kou Qiang Yi Xue Za Zhi 21(4):259-262
13. Igney FH, Krammer PH (2005) Tumor counterattack: fact or fiction? Cancer Immunol Immunother 54(11):1127-1136. doi:10.1007/s00262-005-0680-7 (Pubitemid 41396816)
14. Schoop RA, Noteborn MH, Baatenburg de Jong RJ (2009) A mouse model for oral squamous cell carcinoma. J Mol Histol 40(3):177-181. doi:10.1007/s10735- 009-9228-z
15. Strati K, Pitot HC, Lambert PF (2006) Identification of bio-markers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 103(38):14152-14157. doi:10.1073/pnas.0606698103 (Pubitemid 44452995)
16. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR (1997) A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 123(1):20-24 (Pubitemid 27043653)
17. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Gorner M, Stanley M, Goon PK (2011) Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 268(11):1541-1547. doi:10.1007/s00405-011- 1714-8
18. Verastegui E, Morales R, Barrera JL, Mueller A, Guzman B, Meneses A, Alfaro G (2002) Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck. Clin Immunol 102(1):37-47. doi:10.1006/clim.2001.5130 (Pubitemid 34095223)
19. Berinstein NL (2009) Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Ann NY Acad Sci 1174:107-117. doi:10.1111/j.1749-6632.2009.04935.x
20. + T cell dysfunction in melanoma patients. J Exp Med 207(10):2175-2186. doi:10.1084/jem.20100637
21. Dutton RW, Bradley LM, Swain SL (1998) T cell memory. Annu Rev Immunol 16:201-223. doi:10.1146/annurev.immunol.16.1.201 (Pubitemid 28183364)
22. Pure E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7(5):213-221 (Pubitemid 32822893)
23. Rosshart S, Hofmann M, Schweier O, Pfaff AK, Yoshimoto K, Takeuchi T, Molnar E, Schamel WW, Pircher H (2008) Interaction of KLRG1 with E-cadherin: new functional and structural insights. Eur J Immunol 38(12):3354-3364. doi:10.1002/eji.200838690
24. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271. doi:10.1146/annurev- immunol-031210-101324
25. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W (2011) Th17 cells in cancer: help or hindrance? Carcinogenesis 32(5):643-649. doi:10.1093/carcin/bgr019
26. Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B (2010) Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 103(8):1245-1254. doi:10.1038/sj.bjc.6605891
27. Lopez-Cabrera M, Santis AG, Fernandez-Ruiz E, Blacher R, Esch F, Sanchez-Mateos P, Sanchez-Madrid F (1993) Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 178(2):537-547 (Pubitemid 23218202)
28. Poulton TA, Gallagher A, Potts RC, Beck JS (1988) Changes in activation markers and cell membrane receptors on human peripheral blood T lymphocytes during cell cycle progression after PHA stimulation. Immunology 64(3):419-425
29. + T cells. Blood 113(26):6619-6628. doi:10.1182/blood-2009-01-199588
30. + T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 174(10):6088-6094
31. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350-354. doi:10.1038/nature05115 (Pubitemid 44435155)
32. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215-4225. doi:10.1128/JVI.02844-06 (Pubitemid 46586915)
33. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, Kato S, Yoshimura A (2006) IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203(6):1391-1397. doi:10.1084/jem.20060436 (Pubitemid 43877600)
34. Matsuda M, Nakamoto Y, Suzuki S, Kurata T, Kaneko S (2005) Interferon-gamma-mediated hepatocarcinogenesis in mice treated with diethylnitrosamine. Lab Invest 85(5):655-663. doi:10.1038/labinvest.3700257 (Pubitemid 40675446)
35. Reiners JJ Jr, Rupp T, Colby A, Cantu AR, Pavone A (1989) Tumor copromoting activity of gamma-interferon in the murine skin multistage carcinogenesis model. Cancer Res 49(5):1202-1206 (Pubitemid 19074837)
36. Xiao M, Wang C, Zhang J, Li Z, Zhao X, Qin Z (2009) IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 69(5):2010-2017. doi:10.1158/0008-5472.CAN-08-3479
37. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, OukkaM, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235-238. doi:10.1038/nature04753